Dermatology

The AJMC® Dermatology compendium is a comprehensive resource for clinical news and expert insights for diseases related to the skin, hair, and nails.

Latest News

Book titled hidradenitis suppurativa | Image Credit: Vitalii Vodolazskyi - stock.adobe.com
Hidradenitis Suppurativa Disproportionately Affects Black, Female Patients

September 25th 2024

A poster presented at the Skin of Color Update reported that hidradenitis suppurativa (HS) disproportionately affects Black patients, women, smokers, and those with public insurance or disabilities.

Semaglutide | Image Credit: Corona Borealis - stock.adobe.com
Semaglutide Improves Hidradenitis Suppurativa in Patients With Obesity

September 24th 2024

Diversity animation | Image Credit: annaspoka - stock.adobe.com
Dermatologist Dissects Rosacea Diagnosis Challenges Among Patients of Color

September 17th 2024

Silhouettes of different skin colors | Image Credit: freshidea - stock.adobe.com
Expert Highlights Need for Greater Diversity in Dermatology Clinical Trials

September 17th 2024

FDA approved stamp | Image Credit: Olivier Le Moal - stock.adobe.com
FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis

September 16th 2024

Topical Therapies for the Treatment of Atopic Dermatitis: Balancing Safety, Efficacy, and Access

Develop a deeper understanding of the atopic dermatitis (AD) patient journey, explore topical therapies and treatment sequencing advancements, and gain insight regarding the payer’s perspective on AD therapies.

Atopic Dermatitis Payer Perspectives
Continuing Medical Education
View All
November 21st 2024

Treatment Gaps in the Management of Generalized Pustular Psoriasis: Enhancing the Role of Managed Care

1.5 Credits / Dermatology, Immunology
November 21st 2024

Advancing Patient Outcomes in Hidradenitis Suppurativa: Updates and Strategies for Managed Care

1.5 Credits / Dermatology

More News

Jason Ezra Hawkes, MD.
December 10th 2022

Dr Jason Ezra Hawkes: Exciting Innovations Shown for Precision Medicine, Research, and Technology in Dermatology

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on the advancement in precision medicine within dermatology and what role genetics, research, and immunology can have for care management going forward.
Physician and patient.
December 8th 2022

Lower Risk of Cardiovascular, Metabolic Outcomes Associated With Rituximab for Pemphigus Treatment

Matthew Gavidia
Patients with pemphigus reported lower risk of myocardial infarction and stroke, among other cardiovascular and metabolic outcomes, when treated with rituximab compared with the first-line corticosteroid-sparing agents azathioprine and mycophenolate mofetil.
Diversity.
December 2nd 2022

Low Diversity Shown Among Medical Students Pursuing Dermatology

Matthew Gavidia
Female allopathic medical students pursuing careers in dermatology were less likely than those pursuing other specialties to be from racial and ethnic groups underrepresented in medicine or be a sexual minority, with a lack of interest in underserved care and public health shown overall.
acne.
December 2nd 2022

Use of PRO Measures Lacking in Acne Vulgaris and Rosacea Clinical Trials, Study Finds

Matthew Gavidia
Patient-reported outcome (PRO) measures were included in approximately one-half of acne vulgaris and rosacea randomized controlled trials, despite their utility in capturing the patient perspective.
acne on a person's jawline
November 28th 2022

Different Factors Impact Quality of Life for Adults and Adolescents With Acne

Justina Petrullo
Researchers found that different factors can negatively impact the Dermatology Life Quality Index scores for adults and adolescents with acne.
Dermatologist examining skin.
November 22nd 2022

CKD Severity, Proteinuria Associated With Risk of Prurigo Nodularis

Matthew Gavidia
Korean patients who had more advanced chronic kidney disease (CKD), defined by estimated glomerular filtration rate of 29 or less vs 90 or more, and presence of proteinuria were associated with greater risk of prurigo nodularis.
diversity.
November 17th 2022

Diversity Trends Among Dermatology Resident Trainees Remain Stagnant, Worse Compared With Other Specialties

Matthew Gavidia
Representation of Black and Latinx resident trainees was shown to be worse in dermatology vs other specialties, and annual representation in dermatology remained unchanged between 2005 and 2020.
Struggling teen.
November 16th 2022

Diagnostic Criteria for Hidradenitis Suppurativa May Overlook Pediatric Patients

Matthew Gavidia
More than a third (42.8%) of pediatric patients with hidradenitis suppurativa did not meet all major diagnostic criteria at the time of diagnosis, particularly due to failure to fulfill the recurrence interval criterion (2 or more lesions within 6 months).
depressed person.
November 11th 2022

Social Impact of Hidradenitis Suppurativa Associated With Worse QOL, Mental Health Burden

Matthew Gavidia
Patients with hidradenitis suppurativa who reported feelings of stigmatization due to their condition had worse quality of life and higher levels of depression and social anxiety vs those not reporting feelings of stigmatization.
Diverse hands of patients.
November 9th 2022

Most Medicaid Plans Cover HPV Vaccination for At-Risk Adults With Dermatologic Conditions

Matthew Gavidia
An analysis of Medicaid coverage found that Mississippi was the only state not to provide coverage for human papillomavirus (HPV) vaccination in adults aged 27 to 45 years.
Jason Ezra Hawkes, MD, MS, FAAD.
November 4th 2022

Dr Jason Ezra Hawkes Reviews Recent Advances, Unmet Needs in Management of Hidradenitis Suppurativa

Matthew Gavidia
Jason Ezra Hawkes, MD, MS, FAAD, board-certified dermatologist and associate professor of Dermatology at the University of California Davis in Sacramento, spoke on challenges in the management of hidradenitis suppurativa (HS), as well as promising therapies in the pipeline that target specific pathways suggested to play a role in the pathogenesis and pathophysiology of the disease.
Emergency department.
November 1st 2022

Hidradenitis Suppurativa ED Readmission Linked to Opioid Prescribing, Medicaid Insurance

Matthew Gavidia
Emergency department (ED) readmission was more common than dermatology follow-up among patients with hidradenitis suppurativa (HS) within 30 and 180 days of initially presenting to the ED, with patients with Medicaid coverage and those who had an opioid prescribed were more likely to return.
Athena Gierbolini, president of Hope for HS.
October 26th 2022

Advocate Discusses Misconceptions, Culturally Sensitive Care for Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), spoke on common stigmas regarding HS and how clinicians can improve consultation through a culturally sensitive approach.
Man scratching rash
October 20th 2022

Review Explores Potential Treatments for Prurigo Nodularis

Julia Bonavitacola
A recent review found that new methods of treatment for prurigo nodularis had promising results, including approaches that target interleukin 31 and its receptor.
doctor in hospital.
October 18th 2022

Exploring Strategies for Timely Diagnosis, Comprehensive Care in Hidradenitis Suppurativa

Matthew Gavidia
Researchers reviewed clinical features of hidradenitis suppurativa and provided strategies to promote earlier identification, differentiation from common mimickers, and timely referrals for multidisciplinary management.
Athena Gierbolini, president of Hope for HS.
October 13th 2022

Advocate Speaks on Diet, Holistic Care in Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), discusses current knowledge on the impact of diet and other holistic care strategies in the management of HS.
Surgery.
October 10th 2022

Assessing Surgical Complications in Management of Hidradenitis Suppurativa

Matthew Gavidia
Approximately 1 in 10 patients with hidradenitis suppurativa (HS) experienced complications related to surgery for HS management, in which extensive resection, using skin flaps or skin grafts as a closure method, was associated with a higher incidence of complications.
Athena Gierbolini.
October 7th 2022

Advocate Addresses Unmet Needs in the Management of Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), discussed several pressing issues that warrant consideration to improve the care management of HS.
Black woman.
October 5th 2022

Worse Outcomes Seen Among Black Patients With Hidradenitis Suppurativa

Matthew Gavidia
Black patients with hidradenitis suppurativa were more likely to experience greater disease severity, emergency department visits, hospitalizations, and surgeries than non-Hispanic White patients.
Doctor and patient.
September 24th 2022

Evaluating Factors Associated With Treatment Satisfaction in Hidradenitis Suppurativa

Matthew Gavidia
Tobacco smoking, depression, and increasing number of comorbidities were associated with reduced treatment satisfaction among patients with hidradenitis suppurativa.
Athena Gierbolini.
September 23rd 2022

Advocate Discusses Surgical, Therapeutic Management of Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), spoke on the surgical and therapeutic interventions she’s had for the management of HS.
Athena Gierbolini.
September 16th 2022

Advocate Details Challenges Faced in Path to Diagnosis for Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected by hidradenitis suppurativa (HS), discussed the misconceptions she faced from clinicians regarding her clinical symptoms of HS prior to diagnosis.
Doctor examining patient.
September 14th 2022

Secukinumab Shows Rapid, Sustained Improvement of Hidradenitis Suppurativa

Matthew Gavidia
SUNSHINE and SUNRISE trial data will be submitted to the FDA as part of Novartis’ Biologics License Application (BLA) for secukinumab in hidradenitis suppurativa.
Athena Gierbolini.
September 9th 2022

Advocate Discusses Physical, Psychological Impact of Hidradenitis Suppurativa

Matthew Gavidia
Athena Gierbolini, president of Hope for HS, a nonprofit advocacy group for those affected with hidradenitis suppurativa (HS), speaks on the quality of life burden she has experienced during her HS disease journey.
Older man.
September 3rd 2022

Pain and Late Onset of Hidradenitis Suppurativa May Affect Employment, Educational Level

Matthew Gavidia
Inactive occupational status and low educational level were associated with pain, late disease onset, and greater number of affected areas in patients with hidradenitis suppurativa.
Brindley Brooks.
August 27th 2022

Advocate Highlights Misconceptions in the Management of Hidradenitis Suppurativa

Matthew Gavidia
Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected by hidradenitis suppurativa (HS), spoke on misconceptions she’s encountered on her HS disease journey and the importance for physicians to be conscientious of their advice to patients.
Doctor and patients.
August 24th 2022

Clinical Features, Management of Acne Fulminans Explored in New Case Report

Matthew Gavidia
A case report of a patient with acne fulminans, a rare form of acne vulgaris, discussed the clinical manifestations of the disease, physical examination findings, and management strategies.
Brindley Brooks, who founded HS Connect.
August 20th 2022

Advocate Speaks on Critical Research Needs in Hidradenitis Suppurativa

Lindsey Mulrooney Matthew Gavidia
Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), spoke on key areas of HS comprehension and management that warrant further investigation in clinical research.
Picture of psoriasis
August 17th 2022

Real-world Data Confirm Early Efficacy of Anti-IL-17A Inhibitors for Psoriasis

Jaime Rosenberg
Treatment with anti-interleukin (IL)-17A inhibitors for psoriasis consistently improved outcomes across primary and secondary endpoints compared with all other approved biologics, and researchers also found differences between anti-IL-17A inhibitors.
Brindley Brooks, who founded HS Connect.
August 13th 2022

Advocate Speaks on Prior Authorization, Insurance-Related Barriers for HS Treatment

Lindsey Mulrooney Matthew Gavidia
Brindley Brooks, who founded HS Connect (HSconnect.org), a patient advocacy group for those affected with hidradenitis suppurativa (HS), discussed step edits and other barriers to treatment caused by insurance requirements in the management of HS.
<123456789>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo